HIMS $LLY $NVO The FDA will discuss 7 peptides for possible inclusion on the 503A Bulks List on July 23 24: BPC 157 KPV TB 500 MOTs C Emideltide Semax BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies : ? The FDA just removed 12 peptides (BPC157, TB500, Epitalon, GHKCu inj., DSIP, MOTSc, Semax, PEGMGF, Melanotan II, LL37, Dihexa, KPV) from Category 2 (donotcompound FDA's Bulks List: Section 503A The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what